2. Academic Validation
  3. Discovery of Potent and Oral Bioavailable MAT2A Inhibitors for the Treatment of MTAP-Deleted Tumors

Discovery of Potent and Oral Bioavailable MAT2A Inhibitors for the Treatment of MTAP-Deleted Tumors

  • ACS Med Chem Lett. 2023 Dec 4;14(12):1876-1881. doi: 10.1021/acsmedchemlett.3c00488.
Qun Li 1 2,  Yang Zang 1 2,  Dan An 1 2,  Lifei Liu 1 2,  Wen Jiang 1 2,  Rongchen Liu 1 2,  Jiangtao Su 3,  Jun Yang 1 2 4,  Lie Li 1 2,  Xuejun Zhang 1 2
Affiliations

Affiliations

  • 1 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc., No. 666 High Tech Avenue, East Lake High Tech Development Zone, Wuhan, Hubei 430075, China.
  • 2 Humanwell Healthcare (Group) Co., Ltd., No. 666 High Tech Avenue, East Lake High Tech Development Zone, Wuhan, Hubei 430075, China.
  • 3 Hubei University of Technology, Wuhan, 430068, China.
  • 4 Humanwell Pharmaceuticals US Inc. 421 Sovereign Court, Ballwin, Missouri 63011, United States.
PMID: 38116423 DOI: 10.1021/acsmedchemlett.3c00488
Abstract

Inhibition of methionine adenosyltransferase 2A (MAT2A) has received significant interest because of its implication as a synthetic lethal target in methylthioadenosine phosphorylase (MTAP)-deleted cancers. Here, we report the discovery of a series of 3H-pyrido[1,2-c]pyrimidin-3-one derivatives as novel MAT2A inhibitors. The selected compound 30 exhibited high potency for MAT2A inhibition and a favorable pharmacokinetic profile. Furthermore, in an HCT-116 MTAP-deleted xenograft model, compound 30 showed better in vivo potency than current clinical compound AG-270.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z